loader image
Sunday, November 23, 2025
75.8 F
McAllen
- Advertisement -

AMA Webinar Provides Update on COVID-19 Therapeutics and Other Treatment Options

Translate to Spanish or other 102 languages!

Fact-based insights on COVID-19 therapeutic drugs and other treatment options from the nation’s highest-ranking subject matter experts. Image for illustration purposes.
Paxlovid and Molnupiravir—two therapeutics used in treating COVID-19. Image for illustration purposes.

Mega Doctor News

- Advertisement -

The AMA’s COVID-19 webinar series continues this week by bringing the physician community the latest fact-based insights on COVID-19 therapeutic drugs and other treatment options from the nation’s highest-ranking subject matter experts.

During the tenth episode in the webinar series, AMA Immediate Past President Susan R. Bailey, M.D. will host several infectious disease experts from the Food and Drug Administration (FDA) to provide physicians with the most up-to-date information on Paxlovid and Molnupiravir—two therapeutics used in treating COVID-19. They will also discuss alternative treatment options for high-risk outpatients with mild-moderate COVID-19. 

 
What: AMA webinar series, episode 10: therapeutics and other treatment options

When:  Tuesday, February 1, 2022, 1 p.m. Central | 2 p.m. Eastern

Who:   Susan R. Bailey, M.D., AMA Immediate Past President

- Advertisement -

Stephanie Troy, M.D., FDA Senior medical officer, Division of Antivirals, Office of Infectious Disease in the Center for Drug Evaluation and Research’s Office of New Drugs

Aimee Hodowanec, M.D., FDA Senior medical officer, Division of Antivirals, Office of Infectious Disease in the Center for Drug Evaluation and Research’s Office of New Drugs

John Farley, M.D., M.P.H., FDA Director of Infectious Diseases in the Center for Drug Evaluation and Research’s Office of New Drugs

Registration: To watch the live webinar, register here

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Current Heart Attack Screening Tools Are Not Optimal and Fail to Identify Half the People Who Are at Risk

Current cardiac screening tools used to prevent heart attacks fail to identify nearly half of the people who are actually at risk of having one, according to a new study led by Mount Sinai researchers.

Don’t Overfill Your Plate or Stomach

We’ve all been there: You’re gathered with family or friends for a delicious holiday meal. You start piling food on your plate, and before you know it, there’s no room left – and you haven’t even made it to the cranberry sauce and sweet potatoes.

UT Health San Antonio Center For Brain Health Celebrates with Ribbon Cutting

University of Texas System and UT San Antonio leaders today hailed “a new era of hope, healing and discovery” for neurological patients and their families with a ribbon-cutting for the UT Health San Antonio Center for Brain Health, a $100 million, 103,000-square-foot facility that will bring specialty care, therapy, diagnostics and research under one ro

Rare Mutation that Predicts Strong Immunotherapy Response in Colorectal Cancer Identified

A new study led by researchers at The University of Texas MD Anderson Cancer Center shows that a specific subset of mutations in the POLE gene is strongly associated with durable responses to immunotherapy in patients with metastatic colorectal cancer (CRC).
- Advertisement -
×